What is included with this book?
Edward R. Zartler, Strategy Consultant, Eli Lilly & Co.; Established the Fragment-based Drug Design paradigm at Eli Lilly.
Michael J. Shapiro, Associate Professor of Pharmacy, University of Maryland School of Pharmaceutical Sciences; Industry experience at Lilley, Novartis and Sandoz.
List of Contributors | p. vii |
Introduction to Fragment-based Drug Discovery | p. 1 |
Designing a Fragment Process to Fit Your Needs | p. 15 |
Assembling a Fragment Library | p. 39 |
Practical Aspects of Using NMR in Fragment-based Screening | p. 63 |
Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses | p. 99 |
Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins | p. 135 |
In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry | p. 159 |
Computational Approaches to Fragment and Substructure Discovery and Evaluation | p. 199 |
Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools | p. 223 |
Capture Methods for Fragment-based Discovery | p. 245 |
Identification of High-affinity [beta]-Secretase Inhibitors Using Fragment-based Lead Generation | p. 261 |
Index | p. 281 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.